Boston Microfluidics (BMF), a Cambridge, Mass.-based developer of blood collection devices, raised $17.5m in Series A funding.
The round was led by Anzu Partners with participation from global life sciences company LabCorp Holdings.
The company intends to use the funds to bolster research and development efforts to continue improving BMF’s existing product line, and to develop new collection devices.
Led by Brandon Johnson, CEO, Boston Microfluidics develops needle-free blood collection devices to simplify testing globally. Its flagship product, the Neotainer™, is a device used in the at-home collection kits offered through LabCorp’s consumer-initiated wellness testing platform, Pixel by LabCorp™.
In addition to the at-home collection kits, Pixel by LabCorp offers certain laboratory testing for purchase to be collected at LabCorp’s patient service centers.
This is the first investment made by Anzu Partners’ second VC fund, which was announced in April 2019.